IJFANS INTERNATIONAL JOURNAL OF FOOD AND NUTRITIONAL SCIENCES
ISSN PRINT 2319 1775 Online 2320 7876

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 8, August 2022

A Review Study on Generic Prescription in India

Piyush Mittal, Professor
College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India
Email id- mittalpiyush23@gmail.com

ABSTRACT: ***Generic drugs play a significant role in India, where the majority of people can afford and rely on them because they are inexpensive and widely available. However, some pharmaceutical companies' licenses were revoked because unsold or banned products of branded drugs, which are manufactured in small plants in the United States, were manufactured in India without approval. There were numerous misunderstandings among manufacturers regarding the proper strategy for bringing generic medications to market, resolving data integrity issues, and the sales and marketing aspects of drugs for a successful outcome. In recent years, India has been subjected to increased inspections by international regulatory bodies. Regulatory bodies have taken a greater number of enforcement actions in cases involving data integrity. Based on the license, impact, and issues involved in this review, it was concluded that what are the current trends in generic drugs and their category, as well as the recommendations to be followed to avoid further issues in the future.***

KEYWORDS: ***Current Issues, Generic Drugs, Legal Hurdles, Potential Changes, Treatment***.

1. INTRODUCTION

On April 17, 2017, while introducing a philanthropy clinic in Surat, Prime Minister Narendra Modi announced that the government planned to introduce legislation requiring specialists to recommend prescriptions by their generic names. The proposal has sparked a lively debate in the media and in the pharmaceutical industry. Despite being the world's fourth-largest producer of pharmaceuticals and accounting for 20% of global prescription needs, India is still unable to provide access to many cutting-edge drugs to a large portion of its population. Despite this, the Prime Minister's empowering words on the subject are said to have roused the wrath of some segment of the pharmaceutical industry, which he, by chance, is aware of, as evidenced by his remarks. The government is not the first to try to prohibit the use of brand names[1]–[4]. The last time the government attempted something similar was in 1978, when the Janata Party was in power. The plan was then shelved after the pharmaceutical industry filed a legal challenge to the order. The new administration aims to sever the link between branded generic manufacturers and physicians in order to lower medication costs.

The Prime Minister's concern is well-founded. If a doctor prescribes a costly marked nonexclusive medication, the patient should have the legal option of approaching the retailer to have it replaced with a more affordable conventional or even another marked generic proportionate, which should function similarly to the endorsed marked nonexclusive. By changing the drug and cosmetic regulations, the Union Health Ministry intends to make prescription of generic medications obligatory. Finance Minister Arun Jaitley stated in the budget a proposal to change the medication and cosmetics regulations to make generic medicines cheaper. “Doctors will have to prescribe only generic medicines,” the person added[5], [6]. They won't be able to choose their own brands.” Instead of giving Crocin, the doctor will be required to mention paracetamol, according to the official. The Medical Council of India would guarantee this by sending out a notice to all physicians. Doctors often prescribe branded goods to their patients, and the government believes that by pushing generic drugs, the

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 8, August 2022

cost of healthcare may be lowered. Generics are medicining whose patents have expired. Under their nonexclusive identities, they are offered either as advertised goods or as misbranded things. International Non-Proprietary names are the short names for these nonexclusive names. For example, paracetamol is the generic name for a pain reliever and fever reducer, while crocin is a brand name for paracetamol[7]–[10].

1.1.The Pharmaceutical Market in India:

In 2008, the government pushed a drugstore chain named Jan Aushadhi to provide low-cost traditional medications. Only a few of these shops have been open in the last nine years, and they have often had stock outs and other problems. Despite the fact that India has seven lakh retail pharmacy store outlets, many rural areas remain neglected. There is about 10,000 Jan Aushadhi. In order to save a few rupees, someone searching for these medications in a city would almost definitely have to go to one of these two Jan Aushadhi shops, causing heavy traffic in the metropolis or traveling from one village to another. In India, buying medicines for a chronic illness like diabetes or hypertension makes more sense.

1.2.Distinction in Value:

It is generally knowledge that brand-name goods are less expensive than their image equivalents. Large corporations also produce well-known brand names at very low prices. The market for home pharmaceutical plans is estimated to be around Rs. 1 lakh crore. Nonexclusive name prescriptions have a market value of about Rs 10,000 crore. Undervalued drugs on the national list of essential medicines (NLEM) 2015 control less than 12% of the total market of Rs. 1 lakh crore. Another 4% of the market is made up of useful medications that are subject to price controls imposed by the legislature under Paragraph 19 of the Drug Price Control Order 2013.

In any case, the closeout of marked goods accounts for 90 percent of the residential Indian pharmaceutical market. Even if the government establishes a rule requiring experts to recommend only brand names, a patient would still purchase a well-known medicine since nonexclusive medications have low edges and are therefore unlikely to be loaded by a retail drug specialist. Along these lines, traditional brand treatments do not ensure that the cost of his medication would be reduced. A generic medication list for samples is accessible in India, along with its indications.

1.3.FDCs (Fixed-Dose Combinations):

Fixed part mixtures account for approximately 45 percent of the whole market and are valued about Rs. 45,000 crores. To endorse these medicines under their traditional names, a specialist must write down the nonexclusive components of the fixed portion mix of each remedy in a clear and concise manner. For example, instead of Augmentin, a specialist creating a corex cure should use chlorpheniramine maleate and codeine phosphate, or amoxicillin and clavulanic acid. These are medications that aren't as complicated. Many fixed portion mixtures sold as multivitamins include 3–10 fixes. Under any case, with 45 percent of the market, getting endorsing experts to write solutions in traditional nomenclature would be a non-starter.

Examples from across the world: To illustrate the point with a couple of examples, using the traditional name or, at the end of the day, “Motel – International Nonproprietary Name” is permitted in 66 percent of Organization for Economic Co-operation and Development (OECD) countries, including the United States, and is required in a few others, including France, Spain, Portugal, and Estonia. In most OECD countries, drug experts may legally replace brand-name medicines with conventional equivalents, while in other countries, such as Denmark, Finland,

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 8, August 2022

Spain, Sweden, and Italy, such substitution is compulsory. Furthermore, in a few distinct countries, medication experts are also required to inform patients about the availability of a less costly alternative.

1.4.Challenge Involved:

The greatest issue will be shifting power from doctors to merchants (e-commerce), which will be a significant danger. The danger of this transfer of power to retailers is that they will promote just those goods that provide greater margins, not necessarily high-quality ones, lowering prices over time. The medicines will be marketed as commodities, commoditizing the whole pharmaceutical business, which is unjust. Unless it is produced in a USFDA authorized facility vs a plant that has been locally approved, the cost of producing a branded-generic and generic-generic medication may be the same for the producer. It will take a long time to transition the company from branded-generic to generic-generic.

Because the quality system, infrastructure, and criteria to ensure that every generic medication is of the same quality and has passed the same quality system are not yet in place in India, the regulatory environment does not offer unlimited possibilities for all pharmaceutical firms. The intention is admirable and deserving. However, since we are not yet prepared, implementation will be difficult. Unfortunately, the issue in our nation is that not all states have the same requirements. But, of course, the fact that most nations that take this route also have significant procurement that is covered by a major national insurance system, which India does not, cannot be compared. The government would use the Rs. 90,000 crore branded pharmaceutical market to promote generics. Pharmaceutical companies may have a difficult time getting off to a good start, as the new administration wants to make it mandatory for doctors to recommend pure nonexclusive medicines rather than the labelled generics that they do today.

With a 90 percent share of the Rs. 1 lakh crore advertising, India, like many other emerging countries, is predominantly a marked nonexclusive play, which means that drugmakers auction these patent medicines via their relationships with specialists. Only protected medicines are marketed under a brand in developed countries, such as the United States, and are promoted via their ties to experts. Off-patent medicines are marketed as pure, unadulterated nonexclusive products without the use of a brand name. It contributes to the lower cost of pure generics. This isn't the most important step; the legislature has taken steps to reduce the cost of pharmaceuticals. It has also discovered 200 drug details, including those for treating illness, under the NLEM, bringing the total number of such medicines to 716. This allowed the government to reduce the cost of cancer tranquilizers by 85 percent.

1.5.Prescribing Generic Medicines Could Make the Pharma Industry a Commodity:

The effort to encourage doctors to choose traditional names is one of the many steps the Indian government has taken to reduce healthcare costs. The most important have been the expansion of the NLEM, which has brought them under cost control, as well as the administration's effort to raise awareness of traditional medicine prices and increase access via the Jan Aushadhi program. A shift from India's current marked conventional model to a conventional nonexclusive model necessitates clarity among experts, drug specialists, and patients about the type of medicines available on the market. However, in India, this assertion is completely false. Because of the nature of medicines, there have been many reports of medications failing quality testing or patients not responding to therapy. The administration's main focus should therefore be on strengthening and engaging the controller. It also needs to make the drug approval procedure more formal.

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 8, August 2022

While the move to a nonexclusive remedy is a good step forward for the consumer, we believe that without quality assurance and awareness, noticeable generics will continue to retain the lion's share of the market. Traditional remedies will merely shift the brand determination capability to a medication expert, which is a negative. In the current state of affairs, organizations' focus will shift to drug experts for the purpose of marketing their medicines. Traditional nonexclusive medicines offer a lot more advantages at the drug store level than marked medications, but the reduced retail cost and lack of value confirmation will make marked medications the preferred choice for drug experts to assign.

1.6.The Medical and Pharmaceutical Community's Voice:

The following are some of the medical and pharmaceutical community's voices/opinions on the benefits and drawbacks of the Indian government's generic prescription initiative:

- This is a nice idea, but it's impractical, according to Chandra Gulhati, a prominent pharmacologist and India's Monthly Index of Medical Specialties overseer. “Almost all medications marketed in India are labeled with a brand name, even nonexclusive medicines.”
- According to Chandra Gulhati, a prominent pharmacologist, about 40% of the 60,000 medicine plans marketed in India are fixed portion mixes, or FDCs, of different pharmacological fixes that are only offered under brand names.
- Many FDCs include four to forty fixings; can experts create a treatment with such a large quantity of fixings and their quantities?
- Experts say the Prime Minister's pledge, although sincere, would be impossible to carry out, citing the Medical Council of India's refusal to approve its petition seeking nonexclusive names for treatments in 2002 and again in 2016.
- Medications with common names may only provide tolerable security since the choice on which drug to administer to patients would shift from the expert to the pharmacist.
- According to a spokesperson from the Organization of Pharmaceutical Producers of India (OPPI), the specialist quiet connection contained “trust and confidence” and was thus distinct from the retailer steady relationship, which was “just value-based” and presumably decided by retailer impulses.
- In an announcement issued to the press, T.K. Kanchana, executive general of the OPPI, stated, "It ends up obvious that any such action (to make nonexclusive names simply obligatory) would cost persistent security."
- “As an intense competition among marketers prompts increasing a physicist, Indian patients may face quality problems without a value advantage,” says D G Shah, secretary-general of the Indian Pharmaceutical Alliance.
- Sujay Shetty, a partner at consulting company PWC, believes that such an arrangement would be very difficult to implement. “How can one establish a distinction based on quality with such a large number of traditional pharmaceutical makers?”
- In response to the government's drive for nonexclusive medicines, Biocon's CMD, Kiran Mazumdar Shaw, said, "Usage will be challenging since we are not prepared at this time."
- The Pharmaceutical Industry's Impact.

According to the India Brand Equity Foundation's March 2017 report, the Indian pharmaceutical industry accounts for about 2.4 percent of the global pharmaceutical industry in value terms and 10% in volume terms, and is expected to grow at a compound annual growth rate of 15.92 percent to US $ 55 billion by 2020 from US $ 20 billion in 2015. Nonexclusive

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 8, August 2022

medicines account for the largest portion of the pie (in terms of value), accounting for 70% of the total. Over-the-counter and prescription drugs account for 21% and 9% of the total, respectively. Around 90% of the conventional market is made up of marked generics.

If the Prime Minister's decision is carried out, we will most likely see distinct modifications in market components, as well as individual organizations display viewpoints, as follows:

- No long-term and significant negative market impact is anticipated, since the National Pharmaceutical Pricing Authority recently increased the prices of 700 essential medicines. In any event, as a consequence of a few distinct factors, certain market fluctuations are possible.
- There may be a significant impact on various companies' (brand) parts of the total industry. Depending on their current agreements and displaying models, as well as their business perspective, some will have a more prominent introduction while others will have a less visible introduction.
- Deals and promotion of nonexclusive players' consumption may be reduced significantly, thus addressing the main issue.
- As the focus of company development shifts to retailers, a significant reduction in the number of field authorities is also possible.
- Nonexclusive drug makers should quickly adapt to “low edge high volume” strategies, leveraging economies of scale.

1.7.Changes in Sales and Marketing Strategies that Could Happen:

If this occurs, the primary promoting focus should shift from primarily item brand advertising and partner commitment for the same to escalated corporate brand showcasing with increasingly serious partner commitment techniques for a better top of mind review as a patient agreeable and minding organization. As a result, the commercial development strategy for marked generics may shift from primarily experts to also top retailers. It is unlikely that the major retailers are interested in the pharmaceutical organization's endorsed "Proceeding with pharmacy instruction in similar or significantly more exceptional places than the specialist."”.

2. DISCUSSION

Generic medication development is difficult since it requires many agreements, patent laws, and no objection certifications from inventors, regulatory organizations, and authority members. It should also be devoid of legal problems and should be able to deal with any issues that may arise from specific people. The formulators faced many difficulties in developing a generic medicine, from the raw ingredients utilized through the final product reaching consumers on the market, including determining the drug's pricing. The present state of generics and the need for possible modifications, as well as methods and important suggestions for overcoming legal problems, were addressed.

3. CONCLUSION

The nation's medication controller assures and has repeatedly said that there is no difference in viability, well-being, or quality profile between any approved marked traditional and its nonexclusive reciprocals. Furthermore, by implementing a feasible track and following a framework for all drugs, such apprehension about misleading conventional medicines, both with and without brand names, may be reduced, if not eliminated entirely. Several large Indian marked traditional producers are included in the disclosed rates of USFDA import restrictions on medicine quality criteria and information honesty. This problem has harmed India's pharmaceutical sector, forcing firms to reassess how they ensure quality and compliance while

Research paper UGC CARE Listed (Group -I) Journal Volume 11, Iss 8, August 2022

still staying in business. Furthermore, the Prime Minister of India has addressed the expensive labeling activity of basic medicines, only for the purpose of increasing business and adversely impacting patients' access to these treatments, with no reasons.

As “the time of ware me medications draws near,” traditional drug makers should quickly adapt to “low edge to large volume” plans of action, using economies of scale and tolerating the unmistakable truth, according to a Forbes article. Indeed, what is going on in the word ware, especially when nonexclusive medicines have been authoritatively and legally called basic goods in India, is something else entirely. In general, the Prime Minister's sensible signal that "Remedies in traditional names be made an essential requirement in India," while preparing for another area of universal health care in India, is backed up by appropriate legal and administrative procedures all around.

REFERENCES:

[1] A. Aravamuthan, M. Arputhavanan, K. Subramaniam, and S. J. Udaya Chander J, “Assessment of current prescribing practices using World Health Organization core drug use and complementary indicators in selected rural community pharmacies in Southern India,” *J. Pharm. Policy Pract.*, 2016, doi: 10.1186/s40545-016-0074-6.

[2] M. Das *et al.*, “Generic versus branded medicines: An observational study among patients with chronic diseases attending a public hospital outpatient department,” *J. Nat. Sci. Biol. Med.*, 2017, doi: 10.4103/0976-9668.198351.

[3] S. Jain *et al.*, “A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines,” *Perspect. Clin. Res.*, 2015, doi: 10.4103/2229-3485.154005.

[4] S. Tripathi and S. Bhattacharya, “Patient Perception about Generic vs. Branded Medicines Prescribed in a Tertiary Care Hospital in Northern India -A Descriptive Study,” *Indian J. Pharm. Pract.*, 2018, doi: 10.5530/ijopp.11.2.19.

[5] S. Nath Sanyal and S. K. Datta, “The effect of perceived quality on brand equity: an empirical study on generic drugs,” *Asia Pacific J. Mark. Logist.*, 2011, doi: 10.1108/13555851111183057.

[6] D. Bhat, K. Koonisetty, and G. Saraswathy, “Periodic Supervision of Drug Prescribing and Rational Drug use Among Anemic Patients of a Developing Nation Using who Prescribing Indicators,” *Value Heal.*, 2018, doi: 10.1016/j.jval.2018.07.854.

[7] S. Nagral, “The cost of drugs: Beyond the supreme court order,” *Economic and Political Weekly*. 2013.

[8] S. Dhale and A. Singh, “Perception of medical professionals and pharmacists towards generic and branded drugs,” *Indian J. Forensic Med. Toxicol.*, 2012, doi: 10.37506/ijfmt.v14i4.12774.

[9] K. R. Singh, A. M. Phatak, and M. A. Sathe, “Beliefs and attitudes of generic versus original drugs among doctors in a tertiary-care hospital in Western India,” *Natl. J. Physiol. Pharm. Pharmacol.*, 2016, doi: 10.5455/njppp.2016.6.23022016127.

[10] D. Gupta, “Use of Generic Vs Branded Drugs in Enteric Fever – A Prospective and Comparative Study,” *Int. Arch. Biomed. Clin. Res.*, 2017, doi: 10.21276/iabcr.2017.3.3.5.